José Sanfélix Genovés-rekin lankidetzan egindako argitalpenak (20)

2024

  1. Long-Term Effect of Home Blood Pressure Self-Monitoring Plus Medication Self-Titration for Patients with Hypertension: A Secondary Analysis of the ADAMPA Randomized Clinical Trial

    JAMA Network Open, Vol. 7, Núm. 5, pp. E2410063

2023

  1. Home Blood Pressure Self-monitoring plus Self-titration of Antihypertensive Medication for Poorly Controlled Hypertension in Primary Care: the ADAMPA Randomized Clinical Trial

    Journal of General Internal Medicine, Vol. 38, Núm. 1, pp. 81-89

2022

  1. Predictive Performance of the FRAX Tool Calibrated for Spain vs. an Age and Sex Model: Prospective Cohort Study with 9082 Women and Men Followed for up to 8 Years

    Journal of Clinical Medicine, Vol. 11, Núm. 9

2020

  1. Primary care doctors’ views on self-monitoring of blood pressure and self-titration among patients with uncontrolled hypertension in Spain. The Adampa trial focus group study.

    BJGP Open, Vol. 4, Núm. 4, pp. 1-12

  2. Trends and Geographical Variability in Osteoporosis Treatment After Hip Fracture: A Multilevel Analysis of 30,965 Patients in the Region of Valencia, Spain

    Journal of Bone and Mineral Research, Vol. 35, Núm. 9, pp. 1660-1667

2019

  1. Improving the accuracy of medication adherence measures using linked prescription and dispensation data: findings from the ESOSVAL cohort of patients treated with osteoporosis drugs

    Current Medical Research and Opinion, Vol. 35, Núm. 9, pp. 1535-1544

2017

  1. Primary and secondary non-adherence to osteoporotic medications after hip fracture in Spain. the PREV2FO population-based retrospective cohort study

    Scientific Reports, Vol. 7, Núm. 1

2015

  1. Overuse and underuse of antiosteoporotic treatments according to highly influential osteoporosis guidelines: A population-based cross-sectional study in Spain

    PLoS ONE, Vol. 10, Núm. 8

2014

  1. Impact on the population of different bone mineral density testing criteria and appropriateness of densitometries in the ESOSVAL cohort, spain

    Journal of Clinical Endocrinology and Metabolism, Vol. 99, Núm. 1, pp. 142-150

  2. Variabilidad en las recomendaciones para el abordaje clínico de la osteoporosis

    Medicina Clinica, Vol. 142, Núm. 1, pp. 15-22

2013

  1. Efficacy of osteoporosis therapies in a network meta-analysis with indirect comparisons: Many concerns for new tools of evidence synthesis?

    Osteoporosis International

  2. Prevalence of osteoporosis in the ESOSVAL cohort: Reply to the comment by Pedrera-Zamorano et al.

    Osteoporosis International

  3. Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort

    Osteoporosis International, Vol. 24, Núm. 3, pp. 1045-1055

  4. Prevalence, determinants, and inappropriateness of calcium supplementation among men and women in a Spanish Mediterranean area: Cross-sectional data from the ESOSVAL cohort

    Journal of Bone and Mineral Research, Vol. 28, Núm. 11, pp. 2286-2294

  5. Vertebral fracture risk factors in postmenopausal women over 50 in Valencia, Spain. A population-based cross-sectional study

    Bone, Vol. 52, Núm. 1, pp. 393-399

2011

  1. Adherence to and appropriateness of anti-osteoporotic treatments in patients aged 50 and over in the Valencia Region (Spain). the ESOSVAL-AD study

    BMC Musculoskeletal Disorders, Vol. 12

  2. Impact of osteoporosis and vertebral fractures on quality-of-life. A population-based study in Valencia, Spain (The FRAVO Study)

    Health and Quality of Life Outcomes, Vol. 9

  3. Prevalence of densitometric osteoporosis and osteopenia in Spain

    Bone

2010

  1. Development and validation of a population-based prediction scale for osteoporotic fracture in the region of Valencia, Spain: The ESOSVAL-R study

    BMC Public Health, Vol. 10

  2. Impact of a multifaceted intervention to improve the clinical management of osteoporosis. the ESOSVAL-F study

    BMC Health Services Research, Vol. 10